MannKind posts transcript of nintedanib DPI Phase 1b results call
MNKD•Phase 1b INFLO-1 results call
MannKind hosted a July 29, 2026 call on Phase 1b INFLO-1 results for nintedanib DPI in IPF, led by CEO Michael Castagna and SVP Respiratory Wassim Fares.
INFLO-1 enrolled 27 IPF patients at 10 U.S. sites; management highlighted no serious adverse events, no GI events, no discontinuations, and no dose reductions.
Safety, cough findings, and next-stage study
Fares said about 60% of active patients reported no cough adverse event, and about 90% had no cough or Grade 1 cough. He said 30% had mild cough and 10% had moderate cough, mostly transient.
Castagna said nintedanib DPI plasma Cmax ran about 6-8 times higher than published nebulized nintedanib at comparable doses, and that oral PK was not replicated in humans.
INFLO-2, a global Phase 2 study, is underway with 210 IPF patients, a 12-week placebo-controlled period and a 24-week open-label extension. The primary focus is safety and tolerability, with FVC as a key endpoint.
